Embryo screening during IVF to increase the chances of successful implantation, pregnancy and birth.
From anywhere in Russia
1.5 calendar days
7 calendar days
12 working days
Lab partners undergo a test biopsy
The final result is reviewed by three of our experts
PGT-A, or preimplantation genetic testing for aneuploidy, is the screening of embryos in an assisted reproductive technology cycle for chromosomal abnormalities before they are transferred into the uterus to increase the chances of achieving a successful pregnancy.
Many factors influence the course of a pregnancy, but the most common cause of an unfavourable outcome is chromosomal abnormalities.
38%–76%the prevalence of chromosomal abnormalities detected in spontaneous abortion, according to world and Russian statistics
In all of these patient groups, an increased incidence of chromosomal abnormalities in embryos is suspected.
At First Genetics, we perform PGT-A using NGS (Next Generation Sequencing). NGS allows the most accurate and fastest selection of embryos without chromosomal abnormalities for transfer.
The NGS method allows all chromosomes of the embryo to be analysed to detect mosaicism and unbalanced chromosomal rearrangements. mosaicism и несбалансированные хромосомные перестройки.
Using PGT-A in an IVF cycle can significantly reduce the risk of implantation failure, pregnancy loss and increase the chances of delivering a healthy child.
A biopsy needle is used to collect cells for analysis. The cells are then sent to the laboratory for testing.
Whole genome amplification (WGA) and library preparation for chip mapping.
Forming a conclusion on the basis of the obtained data.
Up to 70%of embryos contain chromosomal abnormalities (numerical or structural)
As the age of the mother increases, the proportion of embryos with chromosomal abnormalities increases significantly and the likelihood of a successful IVF attempt without genetic testing decreases significantly.
Such aneuploid embryos can be selected for transfer because they are not visually different from embryos without chromosomal abnormalities.
On day 3-5the embryo is biopsied from the trophectoderm cells and PGT-A is performed
PGT-A identifies and selects an embryo without chromosomal abnormalities, which increases the chances of implantation and pregnancy.
Statistically, pregnancies with the help of ART occur in about 30-40% of cases.
Conducting test biopsies, monitoring compliance with transport and storage regimes
Minimisation of errors through a more user-friendly protocol for merging and cleaning libraries, automation of sample preparation
Independent interpretation and data analysis by three specialists, minimising subjective decisions — developing and training a neural network.
The NGS method analyses all chromosomes of the embryo and detects mosaicism and unbalanced chromosomal rearrangements
Years of experience in genetics, laboratory diagnostics and bioinformatics
All data is strictly confidential and cannot be passed on to third parties
You can get an online consultation regarding the results of test
Extensive control at each stage of testing
Free delivery of biomaterial across Russia
Any of our partner clinics provides a PGT service, which is carried out in the First Genetics laboratory.